Journey MedicalDERM +6.43%63 PS Ratio is 2.62 as of Jun. 29, 2026, which is 132% above its 10-year median of 1.13. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.17 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 949 Drug Manufacturers companies, Journey Medical ranks worse than 56.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Journey Medical's share price is $6.62.
Journey Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.53. Hence, Journey Medical's PS Ratio for today is 2.62.
The historical rank and industry rank for Journey Medical's PS Ratio or its related term are showing as below:
DERM'
s PS Ratio Range Over the Past 10 Years
Min: 0.27 Med: 1.13 Max: 3.54
Current: 2.62
During the past 7 years, Journey Medical's highest PS Ratio was 3.54. The lowest was 0.27. And the median was 1.13.
DERM's PS Ratio is ranked worse than 56.16% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs DERM: 2.62
Journey Medical Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Journey Medical was -5.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -15.00% per year.
During the past 7 years, Journey Medical's highest 3-Year average Revenue per Share Growth Rate was 25.50% per year. The lowest was -23.70% per year. And the median was -9.65% per year.
Back to Basics: PS Ratio
Journey Medical (NAS:DERM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Journey Medical PS Ratio Related Terms
Journey Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Journey Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Journey Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Journey Medical's Share Price of today is $6.62. Journey Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Journey Medical (DERM) has a PS Ratio of 2.62 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Journey Medical and its competitors. This is 132% above median its historical median of 1.13. Over the past decade, Journey Medical's PS Ratio has ranged from 0.27 to 3.54. According to the industry distribution chart, Journey Medical ranks #533 out of 949 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is Journey Medical's PS Ratio too high?
Journey Medical's current PS Ratio of 2.62 is 132% above median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 3.54. The Drug Manufacturers industry median PS Ratio is 2.25. Journey Medical's value of 2.62 is 16.4% above this industry median. Based on the distribution chart, Journey Medical ranks #533 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's PS Ratio compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #533 out of 949 companies for PS Ratio. This places Journey Medical in the lower half of its industry. The industry median PS Ratio is 2.25. Journey Medical's value of 2.62 is 16.4% above this benchmark. Historically, Journey Medical's own PS Ratio has ranged from 0.27 to 3.54 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 2.25, Journey Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.25, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current PS Ratio of 2.62 is 16.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current PS Ratio is 2.62, which is 132% above median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.17, compared to a current price of $6.62 — trading 58.8% above its estimated fair value. The current PS Ratio is 2.62, which is 132% above median its 10-year median of 1.13 and 16.4% above the Drug Manufacturers industry median of 2.25. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Journey Medical (DERM), the current PS Ratio is 2.62 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.62 is trading 58.8% above its estimated GF Value™ of $4.17.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
PS Ratio: 2.62 (132% above median its 10-year median of 1.13)
GF Value™: $4.17 vs. price of $6.62 (58.8% above fair value)
Industry Position: 16.4% above the Drug Manufacturers median (#533 of 949)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score
Get the complete analysis for DERM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
